EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19

Jasmin K Sidhu, Matthew K Siggins iD, Felicity Liew iD, Clark D Russell, Ashley S S Uruchurtu, Christopher Davis, Lance Turtle iD, Shona C Moore, Hayley E Hardwick, Wilna Oosthuyzen, Emma C Thomson iD, Malcolm G Semple iD und 4 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Jasmin K Sidhu und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Cytokines, Inflammation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UK Coronavirus Immunology Consortium, Imperial College London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While inflammatory and immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in peripheral blood are extensively described, responses at the upper respiratory mucosal site of initial infection are relatively poorly defined. We sought to identify mucosal cytokine/chemokine signatures that distinguished coronavirus disease 2019 (COVID-19) severity categories, and relate these to disease progression and peripheral inflammation.

Methods

We measured 35 cytokines and chemokines in nasal samples from 274 patients hospitalized with COVID-19. Analysis considered the timing of sampling during disease, as either the early (0–5 days after symptom onset) or late (6–20 days after symptom onset) phase.

Results

Patients that survived severe COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-γ, CXCL10, and CXCL13) early in infection. These early mucosal responses were absent in patients who would progress to fatal disease despite equivalent SARS-CoV-2 viral load. Mucosal inflammation in later disease was dominated by interleukin 2 (IL-2), IL-10, IFN-γ, and IL-12p70, which scaled with severity but did not differentiate patients who would survive or succumb to disease. Cytokines and chemokines in the mucosa showed distinctions from responses evident in the peripheral blood, particularly during fatal disease.

Conclusions

Defective early mucosal antiviral responses anticipate fatal COVID-19 but are not associated with viral load. Early mucosal immune responses may define the trajectory of severe COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2CytokinesInflammationHumansMaleFemaleMiddle AgedAgedImmunity, MucosalViral LoadAdultChemokinesSeverity of Illness IndexNasal Mucosa

Stichwörter der Autor:innen

COVID-19SARS-CoV-2airwaychemokinecytokinelungmucosanosevirus

Substanzen

CytokinesChemokines

Autor:innen und Institutionen

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom.
  • Medical Research Council Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Department of Clinical Infection, Microbiology, and Immunology, University of Liverpool, Liverpool, United Kingdom.
  • Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom.

ORCID-Profile: Matthew K Siggins, Felicity Liew, Lance Turtle, Emma C Thomson, Malcolm G Semple, J Kenneth Baillie, Peter J M Openshaw, Ryan S Thwaites

Förderung

  • Medical Research Council
  • UK Coronavirus Immunology Consortium
  • Imperial College London
  • Wellcome Trust
  • U.S. Food and Drug Administration
  • Liverpool Experimental Cancer Medicine Centre
  • Public Health England
  • Bill and Melinda Gates Foundation

Zitieren

APA

Sidhu, J. K., Siggins, M. K., Liew, F., Russell, C. D., Uruchurtu, A. S. S., Davis, C., Turtle, L., Moore, S. C., Hardwick, H. E., Oosthuyzen, W., Thomson, E. C., Semple, M. G., Baillie, J. K., Openshaw, P. J. M., Thwaites, R. S., & ISARIC4C investigators (2024). Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad590

Vancouver

Sidhu JK, Siggins MK, Liew F, Russell CD, Uruchurtu ASS, Davis C, et al. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad590

BibTeX
@article{Sidhu2024,
  author = {Sidhu, Jasmin K and Siggins, Matthew K and Liew, Felicity and Russell, Clark D and Uruchurtu, Ashley S S and Davis, Christopher and Turtle, Lance and Moore, Shona C and Hardwick, Hayley E and Oosthuyzen, Wilna and Thomson, Emma C and Semple, Malcolm G and Baillie, J Kenneth and Openshaw, Peter J M and Thwaites, Ryan S and ISARIC4C investigators, ISARIC4C investigators},
  title = {Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad590}
}
Kostenlos starten →